April 15, 2021
Moores Cancer Center at UC San Diego Health is among the few clinical trial sites in the U.S. for the Pancreatic Cancer Action Network’s (PanCAN) newly created Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
November 14, 2011
…without causing some of the negative effects of current therapies.
December 20, 2023
In a groundbreaking development in the field of anti-acne therapies, a team of researchers has created an acne vaccine that, when used in a mouse acne model, neutralizes a specific variant of an enzyme produced by an acne-associated bacteria while leaving the healthy bacterial enzyme intact.
July 2, 2021
UC San Diego studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers.
November 21, 2022
UC San Diego Alpha Stem Cell Clinic awarded $8M to expand clinical trials of novel stem cell therapies. The CIRM award will advance partnerships between academic and industry experts in San Diego to expedite clinical trials for patients with difficult-to-treat diseases.
August 27, 2018
Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.
September 27, 2017
…tried unsuccessfully to directly target mutant KRAS proteins as a means to treat tumors. Instead of targeting mutant KRAS itself, researchers at University of California San Diego School of Medicine are now looking for other genes or molecules that, when inhibited, kill cancer cells only when KRAS is also mutated.
October 4, 2016
…care by investigating new therapies as well as offering innovative clinical trials and the latest treatments with a personalized medicine approach. This expertise led to the selection of Moores Cancer Center as one of 12 clinical trial sites for the Pancreatic Cancer Action Network’s newly created Precision Promise, the first…
October 15, 2019
UC San Diego bioengineers are a step closer to making CAR T-cell therapy safer, more precise and easy to control. They developed a system that allows them to select where and when CAR T cells get turned on so that they destroy cancer cells without harming normal cells.
July 8, 2021
Treatment provides non-opiate alternative that is minimally invasive with emphasis on functional restoration.
